LTFS
ADAP

Ladenburg Thalmann Financial Services’s Adaptimmune Therapeutics ADAP Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-500
Closed -$2K – 5253
2019
Q1 		$2K Sell
500
-435
-47% -$2.02K ﹤0.01% 4904
2018
Q4 		$6K Buy
935
+800
+593% +$5.9K ﹤0.01% 4491
2018
Q3 		$2K Buy
+135
New +$1.42K ﹤0.01% 4841

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Ladenburg Thalmann Financial Services's ADAP Position: Q2 2019 in Review

Ladenburg Thalmann Financial Services sold out of Adaptimmune Therapeutics (ADAP) in Q2 2019, closing a stake of 500 shares — an estimated $2K sold.

Ladenburg Thalmann Financial Services first reported a position in ADAP in Q3 2018 and held it in 3 quarters. The position peaked at $6K in Q4 2018. 59 funds tracked by Wall St. Rank hold ADAP as of Q2 2019.

  • Ladenburg Thalmann Financial Services reported no remaining Adaptimmune Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 500 Adaptimmune Therapeutics shares in Q2 2019, an estimated $2K.
  • Ladenburg Thalmann Financial Services first reported a position in Adaptimmune Therapeutics in Q3 2018 and held it in 3 quarters.
  • Ladenburg Thalmann Financial Services's Adaptimmune Therapeutics position peaked at $6K in Q4 2018.
  • 59 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q2 2019, filed 15 Aug 2019.